<DOC>
	<DOC>NCT02811159</DOC>
	<brief_summary>To determine the safety of extended treatment with Proellex in women who have successfully completed either study ZPV-201 or ZPU-203 and meet eligibility criteria.</brief_summary>
	<brief_title>An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids</brief_title>
	<detailed_description />
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<criteria>Completed either study ZPV201 or ZPU203 Agreement not to attempt to become pregnant during the trial Agreement to use alcohol in moderation and record the daily consumption (note: elevated liver enzymes may result in discontinuation from the study) Ability to complete a daily subject diary and study procedures in compliance with the protocol Women of childbearing potential must be willing to use doublebarrier contraception during the study and offdrug intervals. Acceptable doublebarrier methods are: male condom with spermicide; male condom with diaphragm; diaphragm containing spermicide plus additional intravaginal spermicide Has a negative pregnancy test at Visit 1 Subject is available for all treatment and followup visits Subject had a significant decrease in bone mineral density while participating in ZPV201 or ZPU203 (total hip or spine measurement decreased by 5% or more) Subject has undergone hysterectomy and/or bilateral oophorectomy since enrollment in ZPV201 or ZPU203. Subject is pregnant or lactating or is attempting or expecting to become pregnant during the entire study period Subjects with abnormally high liver enzymes or liver disease. (ALT or AST exceeding 2 x ULN AND total bilirubin exceeding 1.5 x ULN at Visit 1 and confirmed on repeat). Subject has a hemoglobin of &lt;7.5 g/dL at Visit 1 Concurrent use of any testosterone, progestin, androgen, estrogen, anabolic steroids, DHEA or hormonal products for at least 2 weeks prior to Visit 1 Use of oral contraceptives in the 30 days preceding screening. Use of DepoProvera® in the preceding 10 months. Use of GnRHas (e.g. Lupron Depot) within 3 months prior to screening (Lupron Depot must have a washout period of 3 months prior to screening) Has an IUD in place Current cervical dysplasia classified as Atypical Squamous Cells of Undetermined Significance (ASCUS) associated with highrisk human papilloma virus (HPV) Current diagnosis of Low/High Grade Squamous Intraepithelial Lesion (LGSIL or HGSIL), endometrial polyps or hyperplasia Observation or history of abnormal endometrial biopsy including the presence of EIN Recent history (within past 6 months) of alcoholism or drug abuse Endometrial stripe ≥18 mm in thickness at Visit 1 (subject may be enrolled with sponsor approval) Subject is currently taking cimetidine or spironolactone or has taken them in the last 30 days Clinically significant abnormal findings on Visit 1 examination and laboratory assessments or any condition which in the opinion of the investigator would interfere with the participant's ability to comply with the study instructions or endanger the participant if she took part in the study.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>47 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>